FIECON (PRIVATE.FIECON)

Overall impact
C (41)

Commentary

FIECON is an average overall performer. With a 'C' rating of 41.0 for overall impact (25th percentile compared to all companies), FIECON ranks 73rd out of 95 industry peers, behind Bureau Veritas, Bain, Hudson Capital and 69 others, and ahead of GXP Engaged, Your.Online, Hackett and 19 others. On top material causes for FIECON's industry (Commercial Services & Supplies), FIECON performs well in Quality Lifelong Education (95.2 score) and Quality Lifelong Education (95.2) and performs poorly in Reduced Inequality (15.3 score), Free, Secure Flow of Information (27.3), Accountable Institutions (37.0) and 15 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.FIECON
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2015
Employees
109
Sector
Industrials
Industry
Professional Services
Sub-industry
Research & Consulting Services
SASB industry
Professional & Commercial Services
Headquarters
United Kingdom
Share classes
PRIVATE.FIECON
Description
FIECON is a health economics consultancy born out of the desire to make a difference in the world we live in. Our founders realised that the best way to make a difference was by putting their expertise to best use – harnessing the power of health economics to bring life-changing products to market. Kuntal Fisher and Mark Fisher established FIECON [FI(SHER) ECON(OMICS] in 2015, following a decade of experience in pharmaceutical companies and healthcare consultancies. Since its inception, FIECON has expanded from the two founders to a team of over 100 professionals, growing our ability to deliver high-quality solutions to our global clients. We are trusted partners to our pharma, med tech, and biotech clients. By respecting the technical and delivering the practical, FIECON provides commercial strategy alongside technical ability (not one or the other). We work creatively to generate ideas that solve our client's problems, but we know it’s about results, so we don’t stop until we know the solutions are implemented and working. Great relationships come from collaboration; we're here to support the commercialisation of life-changing products for our pharma, med tech, and biotech clients and make a difference in the world.
Material causes
Ethos considers the following causes material for FIECON, based on its industry sub-industry Research & Consulting Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.